Breadcrumbs
- Home
- Research
- Research events
- The Undergraduate Research Conference
- 2027: Cracking the Cancer Code
Cracking the Cancer Code: Pathways to Pathogenesis
15th LMPSU conference
The Laboratory Medicine and Pathobiology Student Union at the University of Toronto proudly presents the 15th installment of our annual conference series: Cracking the Cancer Code: Pathways to Pathogenesis.
Join us this January as we take a deep dive into the innovative research conducted by renowned scientists on the mechanisms behind cancer pathobiology.
This conference will shed light on the history of cancer research, the pathological and cellular underpinnings of the disease and the advancing of therapies from bench to bedside. Come learn about the most recent developments in this field and their potential to revolutionize our approach to the diagnosis and treatment of cancer.
Where & when
Saturday, January 16, 2027
9:00 am - 3:30 pm, breakfast from 8:30 am
MacLeod Auditorium (MSB 2158) and C. David Naylor Student Commons
1 King's College Cir.
Toronto, Ontario, M5S 1A8
Who this conference is for
This conference is free and open to all! We welcome all interested learners, faculty and alumni from the University of Toronto.
You can contact the LMPSU committee at lmpexecs@gmail.com.
Find out what happened at past LMPSU conferences in our news story Navigating Neurodegeneration: LMPSU's successful conference on brain matter.
Information for attendees
The Agenda
9:00 - 9:30 am - Registration & Breakfast
9:30 - 9:45 am - Opening Remarks, Dr. Rita Kandel, Chair, Department of Laboratory Medicine and Pathobiology (LMP)
9:45 - 10:15 am - Historic Perspective Lecture, Dr. Paul Hamel, LMP, University of Toronto
10:15 - 11:00 am - Keynote Lecture, Dr. Cynthia Hawkins, The Hospital for Sick Children (SickKids)
11:00 - 11:15 am - Coffee Break
11:15 - 11:45 am - Dr. Kelsie Thu, St. Michael’s Hospital, Unity Health Toronto
11:45 - 12:15 pm - Dr. Peter Dirks, The Hospital for Sick Children (SickKids)
12:15 - 1:15 pm - Lunch Break
1:15 - 1:45 pm - Dr. Claudia Gentile, LMP, University of Toronto
1:45 - 2:15 pm - Dr. Michael Ohh, LMP, University of Toronto, MaRS Centre
2:15 - 3:30 pm - Concurrent sessions:
- Panel I: Basic Science & Translational Research with Dr. Michael Ohh, Dr. Claudia Gentile
- Panel II: Clinical Perspectives & Patient Care with Dr. Susan Done, Dr. Paul Kongkham
- Panel III: Industry, Innovation & Commercialization with Dr. Tak Mak, Dr. Ralph Dacosta
Photography and videos
We will be taking photographs and recording some videos for departmental purposes.
If you do not wish to be in any of the photos or videos, please make yourself known to the person taking pictures or videos.
Speaker biographies
See below for speaker information.
Keynote speaker: Dr. Cynthia Hawkins
Dr. Cynthia Hawkins, is an internationally recognized Pediatric Neuropathologist at the Hospital for Sick Children in Toronto where she is Head of the Division of Pathology, Medical Director of Translational Molecular Pathology and a Senior Scientist. She is a Professor of Laboratory Medicine and Pathobiology at the University of Toronto, holds a Garron Family Chair in Childhood Cancer Research and is a Fellow of the Royal Society of Canada and of the Canadian Academy of Health Sciences. Her research focuses on pediatric brain tumors, particularly glioma, with more than 400 peer-reviewed publications, 75,000 citations and an h-index of 106. Dr. Hawkins is also part of the editorial team for the WHO CNS tumour classification and contributes to multiple committees advancing precision medicine in pediatric neuro-oncology.
Dr. Kelsie Thu
Kelsie Thu is a Scientist at the Keenan Research Centre for Biomedical Science at St. Michael’s Hospital and an Assistant Professor at the University of Toronto in the Laboratory Medicine and Pathobiology Department. She holds a tier II Canada Research Chair in Lung Cancer Therapy Response. Her academic training included undergraduate studies at Simon Fraser University, a PhD degree at the University of British Columbia and BC Cancer Research Centre, and a postdoctoral fellowship at the Princess Margaret Cancer Centre.
The Thu Lab seeks to identify molecular mechanisms that promote tumour growth, progression, and drug resistance in lung cancer. Dr. Thu’s team integrates clinical and functional genomics to drive biological discovery in cell and animal models. Using this approach, the Thu Lab aims to discover new and improved ways of treating lung tumors, including strategies to overcome resistance to chemotherapy and EGFR-targeted therapy. The team is also developing a novel virus-based immunotherapy to treat lung and other cancers.
Dr. Peter Dirks
Dr. Peter Dirks is a Professor of Surgery and Molecular Genetics at the University of Toronto, where he holds a Harold Hoffman/Shopper Drug Mart Chair in Pediatric Neurosurgery at the Hospital for Sick Children. He is currently Chief of Neurosurgery and a Senior Scientist in the Developmental and Stem Cell Biology Program. He is a Fellow of the Royal Society of Canada.
Dr. Dirks received his MD from Queen's University (1989) followed by a PhD in at the University of Toronto (1997). He completed neurosurgery training at the University of Toronto (1998) and a pediatric neurosurgery fellowship at Necker Enfants Malades in Paris (1998). Dr. Dirks joined the neurosurgery staff at SickKids in 1998, developing a clinical focus in surgical neuro-oncology and neurovascular disorders.
In 1999, he established his research laboratory in the Arthur and Sonia Labatt Brain Tumour Research Centre at SickKids where in 2004 he was the first to prospectively identify cancer stem cells in human brain tumours, contributing to a paradigm shift in understanding solid cancer growth, and putting emphasis on stemness properties both experimentally and conceptually in the study of primary brain tumours. His research interests continue to lie with the intersection of cancer biology with stem cell and developmental biology, with a focus on uncovering the origins and mechanisms of growth and evolution of glioblastoma and medulloblastoma. He has published nearly 250 papers with 53,000 citations and an h-index of 90. Over his career he has directly mentored over 23 graduate students and 14 postdoctoral fellows.
Dr. Claudia Gentile
Dr. Gentile received her undergraduate degree in Biology, Specialization Cell and Molecular Biology at Concordia University in Montreal, Canada. She then pursued her graduate studies in the laboratory of Dr. Marie Kmita at the IRCM in Montreal and obtained her PhD from McGill University in 2019. Her graduate work focused on investigating the role of Polycomb group proteins in 3D chromatin conformation and HoxA gene regulation during mouse embryonic limb development. Next, she completed her postdoctoral training in the laboratory of Dr. Cigall Kadoch at the Dana-Farber Cancer Institute, Harvard University and the Howard Hughes Medical Institute in Boston. Her postdoctoral work was centered on understanding the functional role of mSWI/SNF chromatin remodelling complexes in oncogene-driven cancers. At the University of Toronto, Dr. Gentile leads a research program focused on how oncogenic cell signaling pathways modulate the activity and function of chromatin regulators to establish transcriptional programs that drive oncogenesis and therapeutic resistance. By combining cancer biology, genomics and biochemistry approaches, she aims to define new strategies for targeting epigenetic dependencies in cancer.
Dr. Michael Ohh
Dr. Michael Ohh is a professor of molecular oncology in the Department of Laboratory Medicine and Pathobiology at the University of Toronto where he has built an impactful academic and research legacy over more than two decades. After earning his Ph.D. from the University of British Columbia and the Terry Fox Laboratory at B.C. Cancer Research Institute, he completed a seminal postdoctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School under Dr. William G. Kaelin Jr., performing foundational research leading to the discovery of the general oxygen-sensing mechanism via the von Hippel-Lindau tumour suppressor that directly contributed to Dr. Kaelin’s shared 2019 Nobel Prize in physiology or medicine. Since establishing his laboratory at the University of Toronto, Dr. Ohh has continued his outstanding scientific achievements, including the unified theory underlying the pathogenesis of VHL disease and other emerging pseudohypoxic syndromes and the discovery of an additional regulatory layer to the canonical RAS GTPase cycle, leading to the revelation of indirect inactivation of RAS, the most commonly mutated oncoprotein driving human cancers that has remained until then ‘undruggable’. Beyond his contributions to science, Dr. Ohh has served as Vice Chair of Life Sciences Education in the Department of Laboratory Medicine and Pathobiology, shaping the academic curriculum and mentoring the next generation of scientists to achieve successful, independent careers at world-class institutions across Canada and around the world. Dr. Ohh is a recipient of numerous awards, including the Bernard and Francine Dorval Prize from the Canadian Cancer Society, the Premier’s Research Excellence Award, and a Canada Research Chair in Molecular Oncology.
Panelist biographies
See below for panelist information.
Dr. Ralph DaCosta
Dr. Ralph DaCosta is an internationally recognized scientist and innovator in the development, clinical translation, and commercialization of advanced optical imaging technologies for cancer and other diseases. With over 30 years of experience in biophotonics and molecular imaging, he is a Senior Scientist at the Princess Margaret Cancer Centre, where he leads a multidisciplinary research program focused on advancing our understanding, diagnosis, and treatment of cancer through innovative imaging technologies.
His laboratory has pioneered the use of intravital optical imaging to visualize and study cancer biology in living models of human disease, particularly pancreatic cancer and leukemia. This work provides new insights into the dynamic interactions between cancer cells and their surrounding microenvironment, including how these interactions influence disease progression, immune responses, and resistance to treatment. These discoveries are helping inform the development of more effective cancer therapies, including novel drug and immunotherapy strategies.
Dr. DaCosta is a Professor in the Department of Medical Biophysics at the University of Toronto's Temerty Faculty of Medicine and has trained numerous graduate students and postdoctoral fellows. He previously held the prestigious Cancer Care Ontario Chair in Cancer Imaging and was named UHN Inventor of the Year in 2013 in recognition of his innovations in surgical oncology and infection imaging. He has led more than 15 single- and multicentre clinical trials evaluating novel imaging technologies, including an international randomized clinical trial combining an FDA-approved fluorescence imaging agent with an intraoperative imaging technology he invented to enable real-time tumour margin assessment during breast cancer surgery.
An inventor on more than 320 patents worldwide, Dr. DaCosta is also the Founder, Chief Scientific Officer, and a Board Director of MolecuLight Inc., a medical imaging company with operations in Toronto, Canada, and Pittsburgh, USA, that has successfully commercialized his fluorescence imaging innovations for wound care and oncology.
Dr. Susan Done
Dr. Susan J. Done is a Professor in the Departments of Laboratory Medicine and Pathobiology, and Medical Biophysics, at the University of Toronto. She is a breast pathologist at the University Health Network and a member of the Princess Margaret Cancer Centre Research Institute. Her research is focused on breast cancer intratumoural heterogeneity, circulating tumour markers, and early events in invasion and metastasis.
Dr. Kongkham
Coming soon!